Grifols Gestione

Gestione criteri di controllo 2/4

Grifols Il CEO è Nacho Abia Buenache, nominato in Apr2024, ha un mandato di meno di un anno. possiede direttamente 0.014% delle azioni della società, per un valore di € 942.54K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.8 anni e 7 anni.

Informazioni chiave

Nacho Abia Buenache

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.01%
Durata media del management	6.8yrs
Durata media del Consiglio di amministrazione	7yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Nacho Abia Buenache (56 yo)

less than a year

Mandato

Mr. Jose Ignacio Abia Buenache, also known as Nacho, serves as Chief Executive Officer of Grifols, S.A. from April 1, 2024 and has been its Director since February 26, 2024. Mr. Abia Buenache had been Chie...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jose Ignacio Abia Buenache	CEO & Director	less than a year	Nessun dato	0.014% € 942.5k
Alfredo Guerra	CFO & VP	17.8yrs	Nessun dato	Nessun dato
Lluis Gomez	Senior Vice President of Strategy & COO Office	no data	Nessun dato	Nessun dato
Nuria Lapeña	VP of Corporate Treasury	no data	Nessun dato	Nessun dato
David Bell	Chief Corporate Development	21.8yrs	Nessun dato	0.0029% € 202.9k
Maria Teresa-Rioné Llano	Chief Communications Officer	6.8yrs	Nessun dato	0.00078% € 53.8k
Camille Alpi	Chief Human Resources & Talent Officer	less than a year	Nessun dato	Nessun dato
Vicente Blanquer Torre	Chief Quality Officer	31.8yrs	Nessun dato	Nessun dato
Sergio Adell	President of Commercial Tech Support	5.8yrs	Nessun dato	Nessun dato
Víctor Grifols Deu	Executive Director	no data	€1.04m	0.016% € 1.1m
Miguel Montblanch	President of Commercial Operations Support	12.8yrs	Nessun dato	Nessun dato
Daniel Coit	Chief Industrial Services Officer	5.8yrs	Nessun dato	Nessun dato

6.8yrs

Durata media

57.5yo

Età media

Gestione esperta: Il team dirigenziale di G0FB è esperto e expertise (durata media dell'incarico 6.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jose Ignacio Abia Buenache	CEO & Director	less than a year	Nessun dato	0.014% € 942.5k
Víctor Grifols Deu	Executive Director	8.5yrs	€1.04m	0.016% € 1.1m
Iñigo Mardones	Independent Director	9.5yrs	€150.00k	Nessun dato
Thomas Glanzmann	Non-Executive Chairman	18.6yrs	€1.90m	0.029% € 2.0m
Juan Twose Roura	Member of the Advisory Committee	9.8yrs	€380.00k	Nessun dato
Raimon Grifols Roura	Vice-Chairman	9.5yrs	€1.04m	0.0060% € 417.4k
Tomas Daga Gelabert	Independent External Director	24.6yrs	Nessun dato	0.045% € 3.1m
Albert Coma-Cros	Proprietary Director	less than a year	Nessun dato	0.0097% € 670.0k
Enriqueta Font	Independent Director	5.5yrs	€125.00k	Nessun dato
Montserrat Abellana	Lead Independent Director	2.4yrs	€63.00k	Nessun dato
Susana Gonzalez Rodriguez	Independent Director	2.4yrs	€63.00k	Nessun dato
Anne-Catherine Berner	Independent Director	less than a year	Nessun dato	Nessun dato

7.0yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di G0FB sono considerati esperti (durata media dell'incarico 7 anni).

Grifols Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Recent updates

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Grifols Receives Fda Approval to Treat Surgical Bleeding in Pediatric Patients with Its Fibrin Sealant Solution

Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

Grifols Announces Management Changes

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Grifols, S.A. to Report First Half, 2022 Results on Jul 28, 2022

Grifols, S.A., Annual General Meeting, Jun 09, 2022

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Grifols, S.A. (BME:GRF) acquired Grifols Escrow Issuer, S.A.U. for $0.06 million.

Grifols to Provide Korean Red Cross with Procleix Panther for Blood Screening, Extending Donor Testing Leadership in Asia

Grifols, S.A. Declares Ordinary Dividend for the Fiscal Year Ended December 31, 2020, Payable on June 7, 2021

Grifols Takes Another Step in the Fight Against Alzheimer's, Partners with Ace to Open First Ambar® Center in Barcelona

Grifols Launches Patient Point-Of-Care System for Monitoring Infliximab in Europe

Grifols, S.A. (BME:GRF) acquired remaining 56% stake in GigaGen, Inc. for $80 million

Grifols, S.A. (BME:GRF) acquired 25 U.S. Based Plasma Donation Centers of BPL Plasma, Inc for $370 million.

Grifols, S.A.(BME:GRF.P) dropped from S&P Global BMI Index

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media